Circulating microRNAs are associated with Docetaxel chemotherapy outcome in castrate-resistant prostate cancer.

Hui-Ming Lin, Lesley Castillo, Kate Mahon, Karen Chiam, Brian Lee, Quoc Nguyen, Michael Boyer, Martin Stockler, Nick Pavlakis, Gavin MARX, Girish Mallesara, Howard Gurney, Susan Clark, Alexander Swarbrick, Roger Daly, Lisa Horvath

    Research output: Contribution to journalArticle

    81 Citations (Scopus)

    Abstract

    Background:Docetaxel is the first-line chemotherapy for castration-resistant prostate cancer (CRPC). However, response rates are ∼50% and determined quite late in the treatment schedule, thus non-responders are subjected to unnecessary toxicity. The potential of circulating microRNAs as early biomarkers of docetaxel response in CRPC patients was investigated in this study.Methods:Global microRNA profiling was performed on docetaxel-resistant and sensitive cell lines to identify candidate circulating microRNA biomarkers. Custom Taqman Array MicroRNA cards were used to measure the levels of 46 candidate microRNAs in plasma/serum samples, collected before and after docetaxel treatment, from 97 CRPC patients.Results:Fourteen microRNAs were associated with serum prostate-specific antigen (PSA) response or overall survival, according to Mann-Whitney U or log-rank tests. Non-responders to docetaxel and patients with shorter survival generally had high pre-docetaxel levels of miR-200 family members or decreased/unchanged post-docetaxel levels of miR-17 family members. Multivariate Cox regression with bootstrapping validation showed that pre-docetaxel miR-200b levels, post-docetaxel change in miR-20a levels, pre-docetaxel haemoglobin levels and visceral metastasis were independent predictors of overall survival when modelled together.Conclusions:Our study suggests that circulating microRNAs are potential early predictors of docetaxel chemotherapy outcome, and warrant further investigation in clinical trials.

    Original languageEnglish
    Pages (from-to)2462-2471
    Number of pages10
    JournalBritish Journal of Cancer
    Volume110
    Issue number10
    DOIs
    Publication statusPublished - 2014

    Fingerprint Dive into the research topics of 'Circulating microRNAs are associated with Docetaxel chemotherapy outcome in castrate-resistant prostate cancer.'. Together they form a unique fingerprint.

  • Cite this

    Lin, H-M., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., MARX, G., Mallesara, G., Gurney, H., Clark, S., Swarbrick, A., Daly, R., & Horvath, L. (2014). Circulating microRNAs are associated with Docetaxel chemotherapy outcome in castrate-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. https://doi.org/10.1038/bjc.2014.181